Skip to Content
en|

Intragroup exemption - EMIR

The following intragroup exemption was granted by Norwegian Finanstilsynet on 18 March 2024 based on Art. 11(7) of the EU EMIR Regulation, i.e. “Regulation (EU) No. 648/2012 of 4 July 2012 on OTC derivatives, central counterparties and trade repositories”:

  • Type of contract: ISDA Master Agreement
  • Between: Equinor ASA and a subsidiary
  • Exemption from: Margining requirements
  • Type of exemption: Full exemption
  • Notional aggregate amount of OTCs (per year) under this exemption: EUR 5.3 million

The following intragroup exemption was granted by Norwegian Finanstilsynet on 6 March 2024 based on Art. 11(9) of the EU EMIR Regulation, i.e. “Regulation (EU) No. 648/2012 of 4 July 2012 on OTC derivatives, central counterparties and trade repositories”:

  • Type of contract: ISDA Master Agreement
  • Between: Equinor ASA and a subsidiary
  • Exemption from: Margining requirements
  • Type of exemption: Full exemption
  • Notional aggregate amount of OTCs (per year) under this exemption: 1 320 million

The following intragroup exemption was granted by Norwegian Finanstilsynet on 23 September 2023 based on Art. 11(7) of the EU EMIR Regulation, i.e. “Regulation (EU) No. 648/2012 of 4 July 2012 on OTC derivatives, central counterparties and trade repositories”:

  • Type of contract: ISDA Master Agreement
  • Between: Equinor ASA and a subsidiary
  • Exemption from: Margining requirements
  • Type of exemption: Full exemption
  • Notional aggregate amount of OTCs (per year) under this exemption: EUR 402 million

The following intragroup exemption was granted by Norwegian Finanstilsynet on 26 October 2022 based on Art. 11(7) of the EU EMIR Regulation, i.e. “Regulation (EU) No. 648/2012 of 4 July 2012 on OTC derivatives, central counterparties and trade repositories”:

  • Type of contract: European Emission Allowances (EUA)
  • Between: Two affiliates, both of which are subsidiaries of Equinor ASA
  • Exemption from: Margining requirements
  • Type of exemption: Full exemption
  • Notional aggregate amount of OTCs (per year) under this exemption: EUR 411 million